$1.04
2.80% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US44975P1030
Symbol
IMAB
Sector
Industry

I-Mab - ADR Stock price

$1.04
-0.30 22.39% 1M
-0.78 42.86% 6M
-0.86 45.26% YTD
-0.68 39.53% 1Y
-59.75 98.29% 3Y
-11.46 91.68% 5Y
-11.46 91.68% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.03 2.80%
ISIN
US44975P1030
Symbol
IMAB
Sector
Industry

Key metrics

Market capitalization $80.10m
Enterprise Value $-123.43m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -112.21
P/S ratio (TTM) P/S ratio 72.82
P/B ratio (TTM) P/B ratio 0.34
Revenue (TTM) Revenue $1.10m
EBIT (operating result TTM) EBIT $-103.06m
EPS (TTM) EPS $-1.55
P/E forward negative
Short interest 1.68%
Show more

Is I-Mab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

I-Mab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a I-Mab - ADR forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a I-Mab - ADR forecast:

Buy
100%

Financial data from I-Mab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1.10 1.10
94% 94%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 43 43
100% 100%
3,914%
- Research and Development Expense 61 61
63% 63%
5,555%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -103 -103
64% 64%
-9,369%
Net Profit -120 -120
66% 66%
-10,939%

In millions USD.

Don't miss a Thing! We will send you all news about I-Mab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

I-Mab - ADR Stock News

Neutral
PRNewsWire
one day ago
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30...
Neutral
PRNewsWire
10 days ago
ROCKVILLE, Md. , Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer ("CEO") effective November 1, 2024.
Neutral
PRNewsWire
16 days ago
ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.
More I-Mab - ADR News

Company Profile

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Head office Cayman Islands
CEO Xi-Yong Fu
Employees 220
Founded 2016
Website www.i-mabbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today